Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
36.23
+0.03 (0.08%)
At close: Dec 12, 2025, 4:00 PM EST
36.26
+0.03 (0.08%)
After-hours: Dec 12, 2025, 7:23 PM EST
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $159.93M in the quarter ending September 30, 2025, with 14.65% growth. This brings the company's revenue in the last twelve months to $630.60M, up 20.63% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$630.60M
Revenue Growth
+20.63%
P/S Ratio
5.61
Revenue / Employee
$487,325
Employees
1,294
Market Cap
3.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
| Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RARE News
- 11 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences - GlobeNewsWire
- 6 weeks ago - Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 7 weeks ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewsWire
- 2 months ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha